Nxstage Medical Earnings: Here’s Why Investors are Buying Shares Now

  Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Nxstage Medical, Inc. (NASDAQ:NXTM) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 5.53%.

These stocks are hitting our Profit Targets. Click here now to discover winning stocks!

Nxstage Medical, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.04 in the quarter versus EPS of $-0.08 in the year-earlier quarter.

Revenue: Rose 14% to $65 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Nxstage Medical, Inc. reported adjusted EPS loss of $0.04 per share. By that measure, the company beat the mean analyst estimate of $-0.05. It beat the average revenue estimate of $63.54 million.

Quoting Management: “As evidenced by our 2012 results, our business and market fundamentals remain strong and positive. We believe NxStage is uniquely positioned for growth as it continues to make a difference to people’s lives with significant innovations that are advancing the standard of renal care,” stated Jeffrey H. Burbank, Founder and Chief Executive Officer.

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business